Bio Path Holdings Inc (BPTH) News

Waaaaaaaay oversold in my opinion.

BPTH delisted from the Nasdaq to the OTC. ***pps dropped 67% from .64 to .21 on 6.2 million volume.

https://otce.finra.org/otce/dailyList?viewType=Additions

BPTH.........................................................a/h

2m floater best dip grab some $1.20s

BPTH......................https://stockcharts.com/h-sc/ui?s=BPTH&p=W&b=5&g=0&id=p86431144783





...................thx..........................................

Was at $5 last week but $1.40 + 40% looks good now

wise alert already down to 3.16 $BPTH 12/19/2024, 8:26:04 AMVote approved for warrants on Dec 12https://t.co/i1Mf5Hj2kc
HC Wainwright
MAKING HUGE $$$ AGAIN pic.twitter.com/aqQCm5Lyho— THE FINAL COUNTDOWN (@THIS_TIME_X) December 19, 2024

$4.05 +500% take those profits $$$

BPTH $3.69 + 453% obesity diabetes 

Still hot $2.88 

bpth...https://stockcharts.com/h-sc/ui?s=bpth&p=W&b=5&g=0&id=p86431144783

this has to shake

bpth..............................https://stockcharts.com/h-sc/ui?s=BPTH&p=W&b=5&g=0&id=p86431144783

Resistance 1.31- 1.51 time to exit trade seems logical zone to cash $$$$$$

Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

BPTH new 52+week low

waiting avg 1.26

BPTH new 52=low

BPTH new 52+week low

BPTH new 52+week low

I for one cannot understand how this stock price gets whacked every single time they PR good news.

a train wreck..geez

Night night

BPTH...................................https://stockcharts.com/h-sc/ui?s=BPTH&p=W&b=5&g=0&id=p86431144783

Flushed

Ouch

Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors

BPTH new 52 week low

The low float, today’s news and myeloid leukemia news should at least stabilize the stock if nothing else. Leukemia PR should have moved it more IMO.

And the news really hasn’t started to make its rounds yet on wire notices. Will be interesting to see what the market feels about these pretty impressive results.

Finally some good news reported today.

https://stonegateinc.reportablenews.com/pr/stonegate-capital-partners-updates-coverage-on-bio-path-holdings-inc-nasdaq-bpth-q1-24

BPTH: Indeed!! (Both the 'Low-Float' and 'Anything-Pharma' theories are now ancient history.)

Crazy that this has traded so many shares and the PPS is still where it currently sits with an incredibly small float of less than 2 million shares….

BPTH: Only 1.56-mil. Float, which might help this too. (But not quite sure if "FLOATS", per se, are trending anymore.)

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

BPTH: Circa where I too grabbed it. (Just when ya think "Cancer" ain't trending anymore.)

FILLED SOME 3.34'S

MOONMAN ON THIS @ 3.50 & 3.30

Boom

BPTH: Bio-Path Holdings Has Been Granted Israeli Patent Number 269608 Titled "COMPOSITIONS COMPRISING P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION FOR USE IN TREATING CANCER OR AUTOIMMUNE DISEASE"
BENZINGA 8:44 AM ET 5/3/2024

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

New hi 3.85 700k float

BPTH new 52 lo

BPTH under $5

Volatility

BPTH: effective Feb. 23,2024 a one for 20 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

October 24, 2023

Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia (AML). The conference call will be held on Monday, October 30, 2023 at 9:00 a.m. ET.
The event will be hosted by Peter Nielsen, Chief Executive Officer of Bio-Path, and will feature presentations and discussion with:

Jorge Cortes, M.D., Director, Georgia Cancer Center, Augusta University
Maro Ohanian, D.O., Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1 study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

https://ih.advfn.com/stock-market/NASDAQ/bio-path-BPTH/stock-news/92348612/bio-path-holdings-to-host-virtual-key-opinion-lead

$BPTH